申请人:Warner-Lambert Company
公开号:US06440966B1
公开(公告)日:2002-08-27
Benzenesulfonamides of formula (I), in which W is OR1, NR2OR1, NRARB, NR2NRARB, or NR2(CH2)2-4NRARB and the other variables as defined in the claims, are inhibitors of MEK and are effective in the treatment of proliferative diseases, cancer, stroke, heart failure, xenograft rejection, arthritis, cystic fibrosis, hepatomegaly, cardiomegaly, Alzheimer's disease, complications of diabetes, septic shock, and viral infection.
式(I)中的苯磺酰胺,其中W为OR1,NR2OR1,NRARB,NR2NRARB或NR2(CH2)2-4NRARB,其他变量如索赔中定义的那样,是MEK的抑制剂,对于治疗增殖性疾病、癌症、中风、心力衰竭、异种移植排斥、关节炎、囊性纤维化、肝大、心脏肥大、阿尔茨海默病、糖尿病并发症、脓毒性休克和病毒感染具有有效性。